首页> 外文期刊>The Journal of Pathology: Clinical Research >Immunoscore in mismatch repair-proficient and -deficient colon cancer
【24h】

Immunoscore in mismatch repair-proficient and -deficient colon cancer

机译:错配修复能力强和缺乏的结肠癌中的Immunoscore

获取原文
           

摘要

Abstract The aim of this study was to investigate immune response and its prognostic significance in colon carcinomas using the previously described Immunoscore (IS). A population-based series of 779 colorectal cancers, operated on between 2000 and 2010, were classified according to tumour, node, metastasis (TNM) status, mismatch repair (MMR), and BRAF mutation status. Rectal cancer cases ( n = 203) were excluded as a high proportion of these patients received preoperative neoadjuvant chemoradiotherapy. Tissue microarray (TMA) samples collected from the tumour centre and invasive front were immunostained for CD3 and CD8. Lymphocytes were then digitally calculated to categorize IS from grade 0 to 4. Samples adequate for IS were available from 510 tumours. IS was significantly associated with AJCC/UICC stage, T stage, lymph node and distant metastases, perineural and lymphovascular invasion, MMR status, and BRAF mutation status. For IS0, IS1, IS2, IS3 and IS4, respectively, the 5-year disease-free survival (DFS) rates were 59, 68, 78, 83 and 94% ( p < 0.001); 5-year disease-specific survival (DSS) rates were 47, 55, 75, 80, and 89% ( p < 0.001); and 5-year overall survival (OS) rates were 40, 44, 66, 61, and 76% ( p < 0.001). IS was also prognostic for DFS, DSS, and OS within subsets of microsatellite-stable (MSS) and microsatellite-instable (MSI) disease. Multivariable analysis showed that IS, AJCC/UICC stage, lymphovascular invasion, and lymph node ratio in AJCC/UICC stage III disease were independent prognostic factors for DFS, DSS, and OS. Age was an independent prognostic factor for DSS and OS. Gender and BRAF mutation were independent prognostic factors for OS. In conclusion, IS differentiated patients with poor versus improved prognosis in MSS and MSI disease and across AJCC/UICC stages. IS, AJCC/UICC stage, lymphovascular invasion, and lymph node ratio in AJCC/UICC stage III disease were independent prognostic factors for DFS, DSS, and OS.
机译:摘要这项研究的目的是使用先前描述的Immunoscore(IS)研究结肠癌的免疫应答及其预后意义。根据肿瘤,淋巴结转移,转移(TNM)状态,错配修复(MMR)和BRAF突变状态,对2000年至2010年之间进行的基于人群的779例大肠癌进行了分类。直肠癌病例(n = 203)被排除在外,因为这些患者中有很大一部分接受了术前新辅助放化疗。对从肿瘤中心和浸润前部收集的组织微阵列(TMA)样品进行CD3和CD8免疫染色。然后对淋巴细胞进行数字计算,将IS从0级分类为4级。可以从510个肿瘤中获得足够的IS样本。 IS与AJCC / UICC分期,T期,淋巴结和远处转移,神经周和淋巴血管浸润,MMR状态和BRAF突变状态显着相关。对于IS0,IS1,IS2,IS3和IS4,其5年无病生存率分别为59%,68%,78%,83%和94%(p <0.001); 5年疾病特异性存活率(DSS)为47%,55%,75%,80%和89%(p <0.001);和5年总生存率分别为40%,44%,66%,61%和76%(p <0.001)。 IS还预示了微卫星稳定(MSS)和微卫星不稳定(MSI)疾病子集中的DFS,DSS和OS。多变量分析表明,AJCC / UICC III期疾病的IS,AJCC / UICC分期,淋巴管浸润和淋巴结比率是DFS,DSS和OS的独立预后因素。年龄是DSS和OS的独立预后因素。性别和BRAF突变是OS的独立预后因素。总之,IS区分了MSS和MSI疾病以及AJCC / UICC各个阶段的预后差与好转的患者。 IS,AJCC / UICC分期,AJCC / UICC III期疾病的淋巴管浸润和淋巴结比率是DFS,DSS和OS的独立预后因素。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号